drugset / Trial / NCT04680091
Drug-Drug Interaction of Pyrotinib With a Moderate CYP3A Inducer
RandomizedParallel-groupOpen-labelTreatment
Summary
This drug-drug interaction (DDI) study had been designed to investigate the effect of a moderate CYP 3A inducer efavirenz on the pharmacokinetics of maleate pyrotinib in Chinese healthy volunteers.
Timeline
- Start
- 2020-11-12
- Primary completion
- 2021-01-28
- Completion
- 2021-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Efavirenz | Other / unclassified | 600 mg | Oral |
| Subject | Pyrotinib | Small molecule | 400 mg | Oral |
Indications
No indication recorded.